Table 3.

Effects of BMI and prognostic factors on progression-free survival after atezolizumab and bevacizumab in univariate and multivariate Cox regression models

	Univariate models		Multivariable models
	Hazard ratio (95% CI)	p value	Hazard ratio (95% CI)	p value
BMI 25 +	0.90 (0.55–1.49)	0.69	0.70 (0.41–1.20)	0.20
BCLC stage (C vs A or B)	1.56 (0.92–2.64)	0.10	1.03 (0.54–1.94)	0.94
CTP class (B vs A)	2.29 (1.35–3.87)	0.002	1.88 (1.04–3.40)	0.04
Tumour size > 7 cm	1.28 (0.76–2.15)	0.36	1.04 (0.61–1.79)	0.88
MVI	2.30 (1.38–3.82)	0.001	1.92 (0.99–3.73)	0.06
Metastatic disease	1.03 (0.60–1.75)	0.92	1.11 (0.62–1.98)	0.74
AFP > 400 ng/dL	1.35 (0.81–2.26)	0.24	1.19 (0.69–2.04)	0.53

95% CI 95% confidence interval, BCLC Barcelona clinic liver cancer, CTP Child-Turcotte-Pugh, MVI Macrovascular invasion, AFP alpha-fetoprotein